Garth Beinart, MD
Basic profileThe University of Texas MD Anderson Cancer Center
Garth Beinart is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 12 publications with 679 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1701 Sunset Blvd
Houston, TX 770051713
Telephone
713-526-5511Registry record last updated 28 Jan 2016.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Tempus AI, IncProgram year20255 payments
- Merck Sharp & Dohme LLCProgram year20252 payments
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.2%PD-1 inhibitor38.7%Pembrolizumab100%Part B, office-administered≥18 patientsAromatase Inhibitor0.2%Anastrozole64%Exemestane19%Letrozole17%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
22.2%Other antiemetics20%Fosaprepitant100%Part B, office-administered≥15 patientsSerotonin-3 Receptor Antagonist1.9%Ondansetron hydrochloride92%Ondansetron Hcl8%Part D + Part B≥41 patients+ 5 more classes in this area
Blood & clotting
18.9%Iron, parenteral preparations18.6%Ferric carboxymaltose100%Part B, office-administered≥14 patientsFactor Xa inhibitor0.2%Eliquis51%Xarelto49%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effects of base excision repair gene polymorphisms on pancreatic cancer survival
International Journal of Cancer
2007
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”